Trials / Completed
CompletedNCT01726023
Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections
A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 486 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effects of Ceftazidime Avibactam plus Metronidazole compared to Meropenem for treating hospitalized patients with complicated intra-abdominal infections.
Detailed description
A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ceftazidime-avibactam | Ceftazidime-Avibactam powder for concentrate for solution for infusion 2000 mg/500 mg |
| DRUG | metronidazole | Metronidazole 500mg/100ml solution for infusion |
| DRUG | Meropenem | Meropenem powder for solution for infusion 1000mg |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2015-03-01
- Completion
- 2015-03-01
- First posted
- 2012-11-14
- Last updated
- 2017-09-06
- Results posted
- 2016-04-14
Locations
30 sites across 3 countries: China, South Korea, Vietnam
Source: ClinicalTrials.gov record NCT01726023. Inclusion in this directory is not an endorsement.